The emergence of Retatrutide in the UK is generating significant excitement within the obesity community. This novel dual compound – targeting both GLP-1 and GIP – promises a potentially new solution to tackling weight challenges. Currently , options have been restricted for many, and Retatrutide represents a encouraging opportunity for individ